Direkt zum Inhalt
Merck
  • Association between salivary cotinine and cardiovascular biomarkers among nonsmokers and current smokers: cross-sectional study of 10,081 participants.

Association between salivary cotinine and cardiovascular biomarkers among nonsmokers and current smokers: cross-sectional study of 10,081 participants.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery (2014-12-03)
L Lu, D F Mackay, D E Newby, J P Pell
ZUSAMMENFASSUNG

Both active smoking and exposure to secondhand smoke (SHS) are associated with cardiovascular disease, but sidestream smoke contains higher levels of small particles and toxic gases than mainstream smoke. The relationship between the concentration of cotinine and a number of cardiovascular biomarkers among nonsmokers and active smokers was examined. A cross-sectional study using the Scottish Health Surveys conducted between 1998 and 2010 was undertaken. Inclusion was restricted to participants aged ≥16 years who had provided saliva and blood samples. Uni- and multivariate regression models were used to examine the relationships between the concentration of cotinine and C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and fibrinogen concentrations, as well as total:HDL cholesterol ratios. Of the 10,018 eligible participants, 7,345 (73.3%) were confirmed to be nonsmokers (cotinine <15.0 ng/mL) and 2,673 (26.7%) were confirmed to be current smokers (cotinine ≥15.0 ng/mL). CRP and total:HDL cholesterol increased, and HDL cholesterol decreased, with increasing cotinine concentration across nonsmokers and smokers (all p < .001). However, there were step changes at the interface, whereby nonsmokers with a high exposure to SHS had lower concentrations of cotinine than light active smokers but comparable concentrations of CRP (p = .709), HDL cholesterol (p = .931), and total:HDL cholesterol (p = .405). Fibrinogen concentrations were significantly raised in moderate and heavy active smokers only (both p < .001). Exposure to SHS is associated with disproportionately higher biomarkers of cardiovascular risk compared with active smoking. Protection from exposure to SHS should be a public health priority.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Cholesterin, Sigma Grade, ≥99%
Sigma-Aldrich
Fibrinogen aus Rinderplasma, Type I-S, 65-85% protein (≥75% of protein is clottable)
Sigma-Aldrich
Fibrinogen aus Humanplasma, 50-70% protein (≥80% of protein is clottable)
Sigma-Aldrich
Cholesterin, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
SyntheChol® NS0-Supplement, 500 ×, synthetic cholesterol, animal component-free, sterile-filtered, aqueous solution, suitable for cell culture
Sigma-Aldrich
Cholesterin, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
Fibrinogen aus Humanplasma, 35-65% protein (≥90% of protein is clottable).
Sigma-Aldrich
C Reactive Protein from human fluids, buffered aqueous solution
Supelco
Cholesterin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Cholesterin -Lösung, certified reference material, 10 mg/mL in chloroform
Supelco
(−)-Cotinine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Fibrinogen from rat plasma, 60-80% protein (≥60% of protein is clottable)
Sigma-Aldrich
(−)-Cotinin, ≥98%
Sigma-Aldrich
Cholesterin, from lanolin, ≥99.0% (GC)
SAFC
Cholesterin, from sheep wool, Controlled origin, meets USP/NF testing specifications
Sigma-Aldrich
Cholesterin, tested according to Ph. Eur.